- Home
- ANAB vs AC Comparison
ANAB vs AC Comparison
Compare ANAB & AC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- AC
- Stock Information
- Founded
- ANAB 2005
- AC 1976
- Country
- ANAB United States
- AC United States
- Employees
- ANAB N/A
- AC N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- AC Investment Bankers/Brokers/Service
- Sector
- ANAB Health Care
- AC Finance
- Exchange
- ANAB Nasdaq
- AC Nasdaq
- Market Cap
- ANAB 759.5M
- AC 809.6M
- IPO Year
- ANAB 2017
- AC N/A
- Fundamental
- Price
- ANAB $22.23
- AC $38.06
- Analyst Decision
- ANAB Buy
- AC
- Analyst Count
- ANAB 10
- AC 0
- Target Price
- ANAB $42.25
- AC N/A
- AVG Volume (30 Days)
- ANAB 559.5K
- AC 3.3K
- Earning Date
- ANAB 05-05-2025
- AC 05-08-2025
- Dividend Yield
- ANAB N/A
- AC 5.89%
- EPS Growth
- ANAB N/A
- AC 16.36
- EPS
- ANAB N/A
- AC 1.80
- Revenue
- ANAB $111,872,000.00
- AC $12,293,000.00
- Revenue This Year
- ANAB N/A
- AC N/A
- Revenue Next Year
- ANAB $9.72
- AC N/A
- P/E Ratio
- ANAB N/A
- AC $20.79
- Revenue Growth
- ANAB 387.20
- AC N/A
- 52 Week Low
- ANAB $12.21
- AC $28.58
- 52 Week High
- ANAB $41.31
- AC $43.85
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- AC 59.65
- Support Level
- ANAB $20.50
- AC $37.52
- Resistance Level
- ANAB $22.84
- AC $38.68
- Average True Range (ATR)
- ANAB 1.28
- AC 0.83
- MACD
- ANAB 0.12
- AC 0.11
- Stochastic Oscillator
- ANAB 83.24
- AC 74.16
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About AC Associated Capital Group Inc.
Associated Capital Group Inc is a diversified global financial services company. It operates in the business of alternative investment management, institutional research services, and cash and other assets through subsidiaries. The activities of its subsidiaries comprise publishing daily research notes and full reports using private market value with a catalyst methodology and also products and customized solutions utilizing private market value with catalyst method of investing.